Literature DB >> 19812882

Successful two-stage correction of ventricular septal defect and patent ductus arteriosus in a patient with fixed pulmonary hypertension.

Aysenur Pac1, Tugcin Bora Polat, Kerem Vural, Mustafa Pac.   

Abstract

We report a case of a 6-year-old boy with fixed severe pulmonary artery hypertension secondary to a ventricular septal defect (VSD) together with a patent ductus arteriosus (PDA). As a preliminary step, PDA embolization was performed following therapy with inhaled prostacyclin over a period of 6 months. Further, the patient underwent successful surgical VSD closure. We postulate that a staged procedure with long-term prostaglandin therapy might be capable of reducing pulmonary artery resistance and permitting total correction in a patient once considered to have inoperable pulmonary arteriopathy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19812882     DOI: 10.1007/s00246-009-9534-y

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  9 in total

Review 1.  Canadian Cardiovascular Society Consensus Conference 2001 update: recommendations for the management of adults with congenital heart disease part III.

Authors:  J Therrien; C Warnes; L Daliento; J Hess; A Hoffmann; A Marelli; U Thilen; P Presbitero; J Perloff; J Somerville; G D Webb
Journal:  Can J Cardiol       Date:  2001-11       Impact factor: 5.223

2.  The regression of pulmonary vascular disease after the creation of pulmonary stenosis.

Authors:  J F DAMMANN; J A McEACHEN; W M THOMPSON; R SMITH; W H MULLER
Journal:  J Thorac Cardiovasc Surg       Date:  1961-12       Impact factor: 5.209

3.  The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt.

Authors:  P WOOD
Journal:  Br Med J       Date:  1958-09-27

4.  Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery.

Authors:  Lucie H Clapp; Paul Finney; Sally Turcato; Sandy Tran; Lewis J Rubin; Andrew Tinker
Journal:  Am J Respir Cell Mol Biol       Date:  2002-02       Impact factor: 6.914

5.  Atrial septal defect closure in a patient with "irreversible" pulmonary hypertensive arteriopathy.

Authors:  Markus Schwerzmann; Moiz Zafar; Peter R McLaughlin; Dean W Chamberlain; Gary Webb; John Granton
Journal:  Int J Cardiol       Date:  2005-07-01       Impact factor: 4.164

6.  Vasodilator and constrictor responses to hypoxia in isolated pig lungs.

Authors:  J T Sylvester; A L Harabin; M D Peake; R S Frank
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1980-11

7.  Successful reversal of pulmonary hypertension in Eisenmenger complex.

Authors:  R J Batista; J L Santos; N Takeshita; L Eocchino; P N Lima; M Goehr; M A Cunha; A T Kawaguchi; T A Salerno
Journal:  Arq Bras Cardiol       Date:  1997-04       Impact factor: 2.000

8.  Incidence of secondary pulmonary hypertension in adults with atrial septal or sinus venosus defects.

Authors:  M Vogel; F Berger; A Kramer; V Alexi-Meshkishvili; P E Lange
Journal:  Heart       Date:  1999-07       Impact factor: 5.994

9.  Multicenter USA Amplatzer patent ductus arteriosus occlusion device trial: initial and one-year results.

Authors:  Robert H Pass; Ziyad Hijazi; Daphne T Hsu; Veronica Lewis; William E Hellenbrand
Journal:  J Am Coll Cardiol       Date:  2004-08-04       Impact factor: 24.094

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.